Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1852W HIGH $2.97
Volume
121.47 K
Value Traded
250.40 K
Short % Float
8.03%
Days to Cover
14.4
0%Week
-11.24%1 Month
-6.83%3 Month
-33.92%6 Month
-72.14%5 Year
-72.26%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
48.44 M
EPS (TTM)
-0.31
P/E Ratio
-
Ent. Value
46.15 M
Total Shares
32.16 M
Float Shares
26.96 M
Insiders
16.24%
Institutions
12.06%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
MDAI Catalyst Timeline
Dated clinical, regulatory and corporate events for Spectral AI, Inc.
Past FDA Catalysts and PDUFA Decisions
How MDAI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Spectral AI, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every MDAI program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DiMaio John MichaelDirector | Grant/Award | 15,000 2,731,847 held | $1.73 | 06/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MDAI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MDAI for Q2 2026. | ||||
Ownership Trends
MDAI Short Interest
Shares sold short, counted twice a month.
8.03%
Short % of Float
of tradable shares sold short
2.2M
Shares Sold Short
-7.7% vs prior count
14.4 Very high
Days to Cover
trading days of normal volume to buy every short share back
150.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MDAI ranks across every disease it competes in
Competitive Position is a premium feature
See how MDAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMDAI News
MDAISpectral AI Schedules 2026 Third Quarter Financial Results and Conference Call
Spectral AI, Inc. will report its third quarter financial results on November 10, 2026. The company will host a conference call at 5:00 pm ET to discuss these results. Spectral AI focuses on AI-driven medical diagnostics, aiming to improve wound care treatment decisions.
Read more →MDAISpectral AI’s DeepView™ System Showcased at the 2026 American College of Emergency Physicians (ACEP) Scientific Assembly
Spectral AI showcased its FDA-cleared DeepView System at the 2026 ACEP Scientific Assembly in Chicago. The system aims to enhance wound care decision-making in emergency departments, addressing the lack of specialized burn expertise. CEO Vincent Capone emphasized its potential to improve patient outcomes by providing timely, data-driven assessments. The event attracted around 7,000 attendees, highlighting its significance in emergency medicine.
Read more →MDAISpectral AI Submits New Technology Add-On Payment (NTAP) Application for DeepView™ System
Spectral AI has submitted a New Technology Add-On Payment (NTAP) application for its DeepView System to CMS. This system, which received FDA De Novo Classification in May 2026, aims to improve reimbursement for hospitals adopting innovative wound care technologies. If approved, the NTAP could significantly enhance patient access to advanced treatment options.
Read more →MDAISpectral AI Announces First Site Initiation Visit for DeepView System™ Clinical Study Supporting Label Expansion Strategy to Burns of the Head, Hands, and Feet
Spectral AI has announced the successful completion of the first Site Initiation Visit for a clinical study aimed at expanding the DeepView System's FDA-cleared burn indication to include burns of the head, hands, and feet. The study, led by Dr. Preetha Muthayya at Pinderfields Hospital, will enroll patients to assess healing potential in these complex areas. This initiative is part of Spectral AI's strategy to enhance the clinical utility of its technology in burn care.
Read more →MDAISpectral AI Announces Upcoming Presentation at ACS Clinical Congress 2026 Highlighting the Use of Artificial Intelligence and Multi-Spectral Imaging in the Assessment of Burn Wounds
Spectral AI, Inc. announced a presentation at the ACS Clinical Congress 2026, focusing on their DeepView System for assessing burn wounds using AI and multi-spectral imaging. Led by Dr. James H. Holmes IV, the presentation aims to broaden awareness of this innovative technology among surgeons. The DeepView System, recently FDA-cleared, offers rapid assessments to improve treatment decisions for burn patients.
Read more →MDAISpectral AI Showcases DeepView® System for Burn Indication and KOL Research at Southern Regional Burn Conference
Spectral AI showcased its DeepView® System at the Southern Regional Burn Conference, highlighting its potential to enhance treatment decisions for burn wounds. The system, which combines AI with multispectral imaging, received positive feedback from clinicians and is backed by FDA's De Novo Classification. The company aims to advance the adoption of this innovative technology in wound care.
Read more →MDAISpectral AI to Present at H.C. Wainwright 28th Annual Global Investment Conference
Spectral AI, Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. CEO Vincent Capone highlighted the recent FDA De Novo Clearance for their DeepView System, which aims to enhance treatment decisions in wound care. The company is on track for its first commercial sales by the end of 2026.
Read more →MDAI▼ -8.2%on this news
Spectral AI Announces 2026 Second Quarter Financial Results
Spectral AI reported a net loss of $4.2 million for the second quarter ended June 30, 2026. The company holds $14.0 million in cash at the end of the quarter. This financial update follows FDA clearance for its DeepView System for burn indication. Management aims to generate first commercial sales by the end of 2026.
Read more →MDAI▲ +5.3%on this news
Spectral AI Schedules 2026 Second Quarter Financial Results and Conference Call
Spectral AI, Inc. will report its second quarter financial results on August 11, 2026, followed by a conference call at 5:00 PM ET. The company focuses on AI-driven medical diagnostics for wound care, particularly for burns, and aims to improve treatment decisions. The DeepView System is designed to provide immediate assessments of wound healing potential.
Read more →MDAISpectral AI Names Darcy Bajko Chief Commercial Officer to Lead Global Sales Launch of FDA-Cleared DeepView® System for Burn Indication
Spectral AI has appointed Darcy Bajko as Chief Commercial Officer to lead the global launch of its FDA-cleared DeepView System for burn indications. This appointment marks a strategic shift for the company as it transitions from product development to commercial execution. Bajko brings extensive experience from leading medical device companies and aims to drive clinical adoption and establish revenue streams.
Read more →MDAIDeepView® System Highlighted at the 2026 British Burn Association Annual Conference
Spectral AI reported that Dr. Jeffrey Carter won first prize at the British Burn Association conference for his presentation on using multispectral imaging with artificial intelligence for burn wounds. The company’s DeepView System received FDA De Novo Classification in May 2024 and UKCA authorization in February 2024. These regulatory approvals support the technology's role in providing immediate assessments of burn wound healing potential.
Read more →MDAISpectral AI Joins the American Board of Wound Management Foundation in Celebrating Wound Healing Awareness Month
Spectral AI, Inc. is partnering with the American Board of Wound Management Foundation to celebrate the 10th Annual Wound Healing Awareness Month. The company highlights its AI-driven DeepView System, which aids in diagnosing burn wounds and improving treatment outcomes. This initiative underscores the importance of timely care for patients with complex wounds.
Read more →MDAISpectral AI to Participate in 2026 British Burn Association Annual Conference
Spectral AI, Inc. will participate in the 2026 British Burn Association Annual Meeting, showcasing its FDA-approved DeepView System for burn wound assessment. The conference, held at Nottingham Trent University, will feature multiple presentations on the technology. The company anticipates its first commercial sales of the DeepView System by the end of 2026.
Read more →MDAISpectral AI Announces Voting Results of Annual Meeting of Stockholders
Spectral AI, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all proposals were approved. The company received FDA clearance for its DeepView System, allowing for commercial distribution in the U.S. Additionally, it secured $31.7 million in funding from BARDA to enhance the system's features. The company is set to initiate commercial sales by the end of 2026.
Read more →MDAI▼ -11.6%on this news· ran to -23% by day 3
Spectral AI Receives FDA De Novo Clearance for DeepView® System for Burn Indication
Spectral AI has received FDA De Novo Classification for its DeepView System, which is designed for assessing burn wound healing potential. This clearance allows the company to begin commercial distribution in the U.S. The DeepView System utilizes AI and multispectral imaging to provide rapid diagnostic assessments, potentially enhancing patient outcomes in burn care.
Read more →MDAI▼ -5.1%on this news
Real-Time Intoxication Detection Platforms Target Expanding Multibillion-Dollar Healthcare Opportunities
MindBio Therapeutics is developing an AI-driven platform that uses voice analysis to detect intoxication in real-time. This innovative approach aims to address the limitations of traditional drug and alcohol testing methods, which are often invasive and slow. The company targets a substantial market in workplace safety and substance testing, estimated at $47 billion. By focusing on multi-substance detection, MindBio is positioning itself at the forefront of a growing field in noninvasive diagnostics.
Read more →MDAI▼ -7.7%on this newsshared move
Spectral AI Announces 2026 First Quarter Financial Results
Spectral AI reported its financial results for Q1 2026, highlighting a net loss of $3.4 million. The company continues to develop its DeepView System under a $31.7 million BARDA contract. Despite a decline in R&D revenue, gross margins improved, and the company reaffirmed its annual revenue guidance of approximately $18.5 million.
Read more →MDAI▲ +5.7%on this news· ran to +17% by day 3
Spectral AI Wins Small Business Innovator Award at Inaugural Texas Innovation Conference
Spectral AI, Inc. received the Small Business Innovator Award at the Texas Innovation Conference for its DeepView System, an AI-driven diagnostic tool for assessing burn wound healing potential. The award acknowledges the company's efforts in transforming medical diagnostics and improving patient care. The DeepView System is designed to provide clinicians with immediate, data-driven assessments to enhance treatment decisions.
Read more →MDAISpectral AI Schedules 2026 First Quarter Financial Results and Conference Call
Spectral AI, Inc. will report its first quarter financial results for 2026 on May 12. A conference call will follow at 5:00 PM ET to discuss these results. The company is focused on advancing medical diagnostics in wound care through its DeepView System, which aims to enhance treatment decisions and patient outcomes.
Read more →MDAISpectral AI’s DeepView® System Showcased at 2026 American Burn Association Annual Meeting
Spectral AI showcased its DeepView System at the 2026 American Burn Association Annual Meeting, highlighting its potential in burn wound assessment. The AI-driven device provides immediate, data-driven evaluations to aid treatment decisions. Clinicians from the U.S. and U.K. presented various studies related to the system, emphasizing its innovative approach to improving patient care.
Read more →About Spectral AI, Inc.
Headquarters2515 MCKINNEY AVE #1000, DALLAS, TX, 75201
BIOPHARMAWATCH ELITE PLUS
Trade the next MDAI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime